Minimizing Patient Risks From COVID-19

As the COVID-19 pandemic continues to be an overwhelming public health concern around the world, there is also rapid progress in both treatment and prevention. Multiple anti-SARS-CoV-2 monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration, though clinicians and patients alike have questions about safety, efficacy, eligibility, access, and implementation. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs, updates to National Institutes of Health guidelines on patient identification and stratification, implementation, and strategies to reduce health care disparities. Patient-clinician interactions will be included to provide examples of optimal communication.